WG
RARE icon

Winton Group’s Ultragenyx Pharmaceutical RARE Stock Holding History

Winton Group’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-8,755
Closed -$409K – 705
2024
Q1 		$409K Buy
+8,755
New +$413K 0.03% 495
2023
Q2 		– Sell
-8,518
Closed -$342K – 1057
2023
Q1 		$342K Buy
+8,518
New +$366K 0.02% 788
2022
Q3 		– Sell
-5,678
Closed -$339K – 1064
2022
Q2 		$339K Buy
+5,678
New +$349K 0.02% 780

Other funds holding RARE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Winton Group's RARE Position: Q2 2024 in Review

Winton Group sold out of Ultragenyx Pharmaceutical (RARE) in Q2 2024, closing a stake of 8,755 shares — an estimated $409K sold.

Winton Group first reported a position in RARE in Q2 2022 and held it in 3 quarters. The position peaked at $409K in Q1 2024. 274 funds tracked by Wall St. Rank hold RARE as of Q2 2024.

  • Winton Group reported no remaining Ultragenyx Pharmaceutical position as of Q2 2024 after selling out during the quarter.
  • Winton Group sold 8,755 Ultragenyx Pharmaceutical shares in Q2 2024, an estimated $409K.
  • Winton Group first reported a position in Ultragenyx Pharmaceutical in Q2 2022 and held it in 3 quarters.
  • Winton Group's Ultragenyx Pharmaceutical position peaked at $409K in Q1 2024.
  • 274 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2024.

Based on Winton Group's 13F filing for Q2 2024, filed 9 Aug 2024.